Stemline Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$35.8M
Lead Investor(s):J.P. Morgan Securities LLC, Cowen and Company, LLC

Estimated Revenue & Financials

  • Stemline Therapeutics's estimated annual revenue is currently $0.5M per year.(?)
  • Stemline Therapeutics received $59.5M in venture funding in January 2018.
  • Stemline Therapeutics's estimated revenue per employee is $3,876
  • Stemline Therapeutics's total funding is $35.8M.

Employee Data

  • Stemline Therapeutics has 129 Employees.(?)
  • Stemline Therapeutics grew their employee count by 2% last year.
  • Stemline Therapeutics currently has 1 job openings.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. A Phase 2 potentially pivotal trial with SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of hematologic cancers, is enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) for which it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Data from this ongoing trial have demonstrated high overall response rates (ORR), with multiple complete responses (CRs). Patients are being followed for response duration and outcomes, and new patients continue to enroll into the study. In addition, ongoing Phase 2 trials with SL-401 are currently enrolling patients with additional malignancies including acute myeloid leukemia (AML) in remission with high risk for relapse including minimal residual disease (MRD) and advanced, high risk myeloproliferative neoplasms (MPN) of unmet medical need. A Phase 1/2 trial in relapsed/refractory multiple myeloma with SL-401 in combination with standard therapies is also enrolling patients. A Phase 2 trial with SL-701, an immunotherapy designed to activate the immune system to attack tumors, in adult patients with second-line glioblastoma multiforme (GBM) is ongoing. A Phase 1 trial with SL-801, a novel oral small molecule reversible inhibitor of XPO1, is currently enrolling patients with advanced solid tumors. For more information about Stemline Therapeutics, visit

keywords:Biotechnology,Healthcare,Marketing,Medical Diagnostics,Pharmaceuticals